Pembrolizumab‐induced acquired perforating dermatosis
Abstract Immune checkpoint inhibitors such as the programmed cell death‐1 (PD‐1) inhibitors, pembrolizumab and nivolumab, are frontline treatments for several types of solid‐organ malignancies. However, cutaneous adverse effects with PD‐1 inhibitor therapy are common and include lichenoid reactions,...
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Liburua |
| Argitaratua: |
Wiley,
2024-12-01T00:00:00Z.
|
| Gaiak: | |
| Sarrera elektronikoa: | Connect to this object online. |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
Internet
Connect to this object online.3rd Floor Main Library
| Sailkapena: |
A1234.567 |
|---|---|
| Alea 1 | Eskuragarri |